Mastectomy for ER Positive Breast Cancer: 141 Real Stories

141 stories match breast cancer, ER positive and mastectomy. 92 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed Central
OutcomeCancer-Free / NED
Jennifer, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Njathi, Female, 40s | Stage II

Biomarkers: Triple-positive; ER-positive; PR-positive; HER2-positive

As of October 2025, Jennifer was more than 1 year past treatment for triple-positive Stage IIA breast cancer and had a recent clear MRI.

City of Hope
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Luminal A solid papillary breast carcinoma with lung metastasis: mastectomy and lung resection, PET-CT clear

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial breast tumor and lung metastasis were ER/PR positive, HER2 0

Metastatic Site: lung

About 40 days after lung surgery, PET-CT showed no abnormalities; the specialist recommended regular follow-up without additional antitumor drug therapy, and she was alive and in good condition.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast CancerBreast Cancer

Hormone receptor-positive male breast cancer: spontaneous regression after biopsy and mastectomy

Patient Info: Anonymized, Male, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative; p63 staining confirmed myoepithelial cells in residual benign cystic lesion

Mastectomy and axillary clearance showed no residual invasive carcinoma or carcinoma in situ, with clear margins; he recovered well and began adjuvant tamoxifen because of the original ER/PR-positive biopsy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage 0 Invasive Ductal CarcinomaBreast Cancer

Stage 0 ER-positive DCIS: mastectomy without adjuvant therapy, followed by successful pregnancy

Patient Info: Anonymized, Female, 40s | Stage 0

Biomarkers: ER-positive; PgR-positive; HER2-negative; nuclear grade 2; comedo type; negative margins; no lymph node involvement

She completed surgical treatment for Stage 0 DCIS with negative margins and no lymph node involvement, avoided adjuvant therapy, resumed assisted reproductive treatment, and delivered a healthy male infant.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage IIIB male encapsulated papillary breast cancer: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: ER-positive 100%; PR-positive 100%; HER2-negative / IHC 1+; p63 loss supported encapsulated papillary carcinoma; no neuroendocrine differentiation

Three years after diagnosis, he was clinically doing well without evidence of breast cancer recurrence after mastectomy, radiation, and tamoxifen.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage 3 breast cancer: complete pathological response to chemotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

At 1-year follow-up, she remained free of breast cancer; a thyroid nodule found on CT had no malignancy on fine-needle aspiration.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

HER2-positive node-positive breast cancer: mastectomy and adjuvant TCbHP

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: HER2-positive breast cancer with ER/PR positivity, PD-L1 CPS 25

Adjuvant TCbHP was initiated after surgery, the first cycle was tolerated with supportive care, and regular monitoring was ongoing without evidence of distant recurrence or metastasis reported.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

HER2-low lobular breast cancer with bone marrow involvement responding to T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

HER2-low lobular breast cancer with bone marrow involvement treated with T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed Central
OutcomeCancer-Free / NED
Courtney, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Courtney's Patient Story

Patient Info: Courtney, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

As of June 2025, Courtney was recovering from Stage III ER-positive, PR-positive, HER2-negative ILC treatment after double mastectomy, Taxotere/Cytoxan chemotherapy, and 25 rounds of radiation, with reconstructive surgery delayed by radiation skin injury.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
A patient, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage 2 secretory breast cancer: surgery alone with clear margins

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: ER-positive; PR-negative; HER2-negative; secretory carcinoma; low grade

At 1-month follow-up after modified radical mastectomy, she had no surgical site infection, no arm lymphedema, no scapular winging, full shoulder range of motion, and no evidence of nodal or distant disease.

PubMed Central
OutcomeCancer-Free / NED
Sara, who was diagnosed with Breast CancerBreast Cancer

HR-Positive Breast Cancer: Sara's Patient Story

Patient Info: Sara Glenn, Female, Under 40

Biomarkers: TP53 mutation / Li-Fraumeni syndrome; ER-positive; HER2-negative

As of June 2025, Sara had completed bilateral mastectomy and reconstruction for ER-positive, HER2-negative breast cancer and was on planned 10-year tamoxifen plus intensive Li-Fraumeni syndrome surveillance for herself and her daughters.

City of Hope
OutcomeCare Ongoing
Tanya, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Tanya's Patient Story

Patient Info: Tanya, Female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 1

As of May 2025, Tanya was recovering from chest wall surgery, ALT flap repair, and a later skin graft after developing angiosarcoma in her radiated reconstructed breast years after Stage IIIA ILC treatment.

Lobular Breast Cancer Alliance
OutcomeSetback / Progression
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage IIIB ER/PR-positive breast cancer: emergency mastectomy for infected fungating tumor

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER >75%; PR >75%; HER2 0 / HER2-negative; grade 3 invasive ductal carcinoma

As of May 2025, management centered on anastrozole after emergency mastectomy, repeated debridements, wound care, and major postoperative complications; oncology follow-up had become inconsistent because of ongoing medical setbacks.

PubMed Central
OutcomeCare Ongoing
Kelsey, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of May 2025, Kelsey had completed chemotherapy, double mastectomy with reconstruction, and 16 radiation sessions, and was continuing tamoxifen with Verzenio planned for 2 years plus Lupron ovarian-suppression shots.

The Patient Story
OutcomeCare Ongoing
LaShae, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: LaShae's Patient Story

Patient Info: LaShae, Female, Under 40 | Stage II

Biomarkers: ER-positive; comprehensive genetic panel negative

As of May 2025, LaShae had completed mastectomy for Stage IIB ER-positive breast cancer with 2 positive lymph nodes and was undergoing chemotherapy, with radiation and 5-10 years of hormone therapy planned.

The Patient Story
OutcomeCare Ongoing